Application of curcumin compound in preparation of pancreatic lipase inhibitor

The screening of curcumin compounds as pancreatic lipase inhibitors through enzyme inhibition and high-performance liquid chromatography analysis has solved the problem of difficulty in inhibiting digestive lipase in the prior art, and the effective extraction of curcumin compounds and pancreatic lipase inhibition has been achieved. Potential drugs for anti-obesity are provided.

CN118924711AInactive Publication Date: 2024-11-12INST OF URBAN AGRI CHINESE ACADEMY OF AGRI SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410967222.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-12
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit digestive lipase, which makes the problem of obesity difficult to solve, and the potential biological activities of curcumin compounds have not been fully utilized.

Method used

Curcumin compounds were screened as pancreatic lipase inhibitors by enzyme inhibitors, centrifugal ultrafiltration combined with high performance liquid chromatography and fluorescence spectroscopy. Curcumin and double demethoxy turmeric were extracted through microwave-assisted extraction and mixed eutectic solvents. The inhibitory mechanism of demethoxycurcumin combined with molecular docking technology is studied.

Benefits of technology

Curcumin compounds significantly inhibit pancreatic lipase activity, improve the bioavailability of dietary fats, provide potential anti-obesity drug candidates, and extraction methods improve the efficiency and purity of the compounds.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924711A_ABST
    Figure CN118924711A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, in particular to application of curcumin compounds in preparation of pancreatic lipase inhibitors. The invention discloses application of a curcumin compound in preparation of a pancreatic lipase inhibitor. The curcumin compound comprises one or more of curcumin, bisdemethoxycurcumin and demethoxycurcumin. The curcumin, the bisdemethoxycurcumin and the demethoxycurcumin have the effect of inhibiting the pancreatic lipase.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of medical technology, and in particular to application of curcumin compounds in the preparation of pancreatic lipase inhibitors. Background Art

[0002] Obesity, a chronic metabolic disease characterized by extreme fat accumulation due to excessive caloric intake or disordered fat metabolism, has gradually become one of the major challenges facing society. In addition, multiple studies have reported that obesity may lead to an increased risk of various chronic diseases, such as type 2 diabetes, hyperlipidemia, osteoporosis, cardiovascular disease, and even certain cancers. Therefore, it is crucial to find a solution to the obesity problem on a global scale. Increasing evidence suggests that reducing the bioavailability of dietary fat by inhibiting digestive lipase may be a potential way to alleviate obesity. As a key lipolytic enzyme, PL is responsible for hydrolyzing approximately 50-70% of dietary fat into absorbable monotriglycerides and fatty acids, suggesting that inhibiting PL activity to reduce systemic breakdown of lipids may be an important target for the prevention and management of obesity.

[0003] Many secondary metabolites found in turmeric, including curcuminoids, demethoxycurcumin and bisdemethoxycurcumin, have been shown to have anti-obesity and lipid-lowering biological activities and may be a potential source for the discovery of potent natural PLIs. Therefore, enzyme inhibition, centrifugal ultrafiltration combined with HPLC analysis combined with fluorescence spectroscopy and molecular docking analysis were used to screen pancreatic lipase inhibitors of turmeric compounds. Summary of the invention

[0004] In order to solve the above problems, the present invention provides the use of curcumin compounds in the preparation of pancreatic lipase inhibitors.

[0005] In order to achieve the above object, the present invention provides the following technical solutions:

[0006] The present invention provides application of a curcuminoid compound in preparing a pancreatic lipase inhibitor. The curcuminoid compound comprises one or more of curcumin, bisdemethoxycurcumin and demethoxycurcumin.

[0007] Preferably, the curcuminoids inhibit pancreatic lipase.

[0008] The present invention also provides a method for extracting curcumin compounds, comprising the following steps:

[0009] 1) mixing turmeric with a deep eutectic solvent, and extracting by microwave-assisted method to obtain an extract;

[0010] 2) Centrifuging the extract obtained in step 1) to obtain a supernatant, and quantifying the supernatant by high performance liquid chromatography to obtain curcuminoids.

[0011] Preferably, in step 1), the solid-liquid ratio of turmeric to the deep eutectic solvent is 1:10-1:20.

[0012] Preferably, the low eutectic solvent in step 1) is choline chloride and lactic acid, and the molar ratio of choline chloride to lactic acid is 2:1-1:2.

[0013] Preferably, the extraction temperature in step 1) is 50-70°C and the extraction time is 10-30 min.

[0014] Preferably, the centrifugal conditions in step 2) include: a rotation speed of 4000 rpm and a time of 5-15 min.

[0015] Beneficial effects of the present invention:

[0016] Curcumin, bisdemethoxycurcumin and demethoxycurcumin have the effect of inhibiting pancreatic lipase. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.

[0018] Figure 1 To screen for potential pancreatic lipase inhibitors in turmeric extracts;

[0019] Figure 2 The pancreatic lipase inhibition strength of curcumin, demethoxycurcumin, and bisdemethoxycurcumin;

[0020] Figure 3 The enzymatic reaction rate v and PL concentration change in the presence of different concentrations of curcumin, demethoxycurcumin and bisdemethoxycurcumin;

[0021] Figure 4 The inhibitory effects and mechanisms of potential PL inhibitors; (A) Reversibility of PL inhibition by curcumin (A1), demethoxycurcumin (A2) and bisdemethoxycurcumin (A3); (B) Linewever-burk hyperbolic curves of PL by curcumin (B1), demethoxycurcumin (B2) and bisdemethoxycurcumin (B3);

[0022] Figure 5The fluorescence quenching effect of potential PL inhibitors on curcumin; (A) Fluorescence spectra of curcumin (A1), demethoxycurcumin (A2) and bisdemethoxycurcumin (A3) on PL (the upper right is the Stern-Volmer plot of inhibitors and PL at 298K and 310K), the concentrations of inhibitors in ag are 0, 0.125, 0.25, 0.5, 1, 2 and 4mM respectively; (B) Double logarithmic plot of the quenching effect of curcumin (B1), demethoxycurcumin (B2) and bisdemethoxycurcumin (B3) on PL fluorescence at 298K and 310K;

[0023] Figure 6 Two-dimensional and three-dimensional graphs of the interactions between pNPB, curcumin, demethoxycurcumin and bisdemethoxycurcumin and PL. DETAILED DESCRIPTION

[0024] The present invention provides an application of a curcuminoid compound in preparing a pancreatic lipase inhibitor, wherein the curcuminoid compound comprises one or more of curcumin, bisdemethoxycurcumin and demethoxycurcumin. In the present invention, the curcuminoid compound inhibits pancreatic lipase.

[0025] In order to further illustrate the present invention, the present invention is described in detail below in conjunction with embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0026] Example 1

[0027] (1) Efficient extraction of main curcumin compounds

[0028] 1.1 Operation method

[0029] 2.0 g of turmeric powder was accurately weighed and placed in a 250 mL three-necked flask. A low eutectic solvent was added in a certain proportion. At a constant temperature of 60 ° C, microwave-assisted extraction was performed according to a certain solid-liquid ratio, low eutectic solvent molar ratio, and extraction time. After the obtained sample was centrifuged, the supernatant was taken, and bisdemethoxycurcumin, demethoxycurcumin and curcumin were quantitatively analyzed by high performance liquid chromatography to obtain the three curcumin extraction rates (mg / g), respectively.

[0030] 1.2 Single Factor Experiment

[0031] 1.2.1 Investigating the effect of solid-liquid ratio on the extraction rate of three curcumin

[0032] According to the method in 1.1, the molar ratio of choline chloride to lactic acid low eutectic solvent was 1:1, the extraction time was 20 min, and the extraction rates of the three curcuminoids were investigated when the solid-liquid ratio was 1:6, 1:12, 1:16, 1:20, and 1:25. The results are shown in Table 1.

[0033] Table 1 Extraction rate of curcuminoids under different solid-liquid ratios (mg / g)

[0034] Material-liquid ratio Bisdemethoxycurcumin Demethoxycurcumin Curcumin 1:6 0.32 0.49 1.40 1:12 0.42 0.65 1.55 1:16 1.09 0.70 2.61 1:20 0.31 0.60 2.31 1:25 0.11 0.19 1.29

[0035] 1.2.2 Effect of the molar ratio of deep eutectic solvents on the extraction rate of three curcumin

[0036] According to the method in 1.1, the solid-liquid ratio was 1:6, the extraction time was 20 min, and the extraction rates of the three curcuminoids were investigated when the molar ratios of choline chloride and lactic acid were 1:1, 1:2, 1:3, 2:3, and 2:5. The results are shown in Table 2.

[0037] Table 2 Extraction rate of curcuminoids under different eutectic solvent ratios (mg / g)

[0038] Choline chloride: lactic acid Bisdemethoxycurcumin Demethoxycurcumin Curcumin 1:1 1.09 0.70 2.61 1:2 0.20 0.33 1.40 1:3 0.39 0.65 1.89 2:3 0.11 0.19 1.14 2:5 0.13 0.21 1.10

[0039] 1.2.3 Investigating the effect of extraction time on the extraction rate of three curcumin

[0040] According to the method in 1.1, the molar ratio of choline chloride to lactic acid low eutectic solvent was 1:1, and the solid-liquid ratio was 1:16. The extraction rates of the three curcuminoids were investigated when the extraction time was 10 min, 20 min, 30 min, 40 min, and 50 min. The results are shown in Table 3.

[0041] Table 3 Extraction rate of curcuminoids under different extraction time conditions (mg / g)

[0042]

[0043]

[0044] 1.3 Orthogonal test

[0045] The extraction rate of three curcumin was used as the investigation index, and the corresponding conditions were optimized according to the results of the single factor experiment. The orthogonal test was used to investigate the effects of the solid-liquid ratio, the molar ratio of choline chloride to lactic acid eutectic solvent, and the extraction time on the extraction rate of the three curcumin. The orthogonal experiment showed that the extraction rate of the three curcumin was the highest when the solid-liquid ratio was 1:16, the solvent molar ratio (molar ratio of choline chloride and lactic acid) was 1:1, and the extraction time was 20 minutes. The results are shown in Table 4.

[0046] Table 4 Orthogonal test results for optimizing the extraction rate of curcuminoids (mg / g)

[0047]

[0048] (2) Pancreatic lipase inhibitory activity of turmeric extracts extracted by different extraction methods

[0049] Pancreatic lipase is an important lipolytic enzyme in lipid absorption and plays an indispensable role in the entire digestion process. 100 μL of plant extracts of different concentrations were added to 200 μL Tris-HCl buffer (50 mM, pH 7.4) and 100 μL PL solution (5 mg / mL). Shake well in a shaker, let stand at 37°C for 20 min, add 100 μL pNPB (2 mM), let stand at 37°C for 15 min, and quickly measure the absorbance of the solution at 410 nm. The sample blank and the control blank were treated in the same way, with oselita as the positive drug. The inhibitory effect (%) was calculated as follows:

[0050]

[0051] The results showed that the IC 50 The value was 9.70±0.29mg / mL, and the IC 50 The value was 7.31±0.47mg / mL, and the IC 50 The value was 23.18±0.81mg / mL, and the IC 50 The value was 38.74±0.34mg / mL, and the IC 50 The value was 43.73±1.47mg / mL, and the IC 50 The value was 45.96±3.02mg / mL, and the IC 50 The value was 62.94±2.70mg / mL, and the IC 50 The value was 65.71±0.32mg / mL, and the IC 50 The value was 76.67±1.76mg / mL, and the IC 50 The value was 92.91±0.38mg / mL, and the IC 50 The value is 107.95±1.08mg / mL, and the IC 50 The value was 132.22±2.49mg / mL, and the IC 50 The value was 142.83±4.83mg / mL, and the IC 50 The value was 150.41±1.12mg / mL, and the IC 50 The value was 152.47±6.75mg / mL, and the IC 50 The value was 172.29±2.67mg / mL, and the IC 50 The value was 214.58±4.06mg / mL, and the IC 50 The value was 243.70±3.99mg / mL, and the IC 50The value was 282.38±1.15mg / mL, and the IC 50 The value was 284.84±4.70mg / mL, and the IC 50 The value was 294.30±6.26mg / mL, and the positive control was Oselta IC 50 The value was 0.36±0.12mg / mL. The results showed that microwave-assisted DES extraction of turmeric could enhance the pancreatic lipase activity of the extract and improve its potential anti-obesity activity.

[0052] (3) Online screening of pancreatic lipase inhibitors from turmeric extract

[0053] Enzyme inhibition, centrifugal ultrafiltration combined with HPLC analysis method were used to screen pancreatic lipase inhibitors from turmeric compounds. 100 μL pancreatic lipase, 100 μL turmeric extract and 200 μL Tris-HCl buffer solution (50 mM, pH 7.4) were mixed and incubated at 37°C for 20 minutes. After incubation, in order to obtain the pancreatic lipase inhibitor complex, the supernatant was centrifuged at 12000×g for 20 minutes using a 10kDa molecular weight centrifuge tube. Then, 200 μL acetonitrile aqueous solution (60%, v / v) was added and centrifuged at 12000×g for 20 minutes to release the ligand, and the filtrate was finally collected for further high-performance liquid chromatography analysis of the changes before and after the binding of bisdemethoxycurcumin, demethoxycurcumin and curcumin to pancreatic lipase. The liquid chromatography results showed that Figure 1 As shown, compared with the chromatogram of the standard substance (black), compounds 1, 2 and 3 represent curcumin, demethoxycurcumin and bisdemethoxycurcumin, respectively. Compared with the control chromatogram (red), the peak areas corresponding to the three compounds in the ultrafiltration chromatogram (green) decreased by 41.37%, 49.33% and 54.69%, respectively, indicating that the above three substances may specifically bind to pancreatic lipase. In addition, three compounds were found in the eluted chromatogram (blue), confirming that the above three substances may specifically bind to pancreatic lipase. These results show (such as Figure 1 As shown in the figure, curcumin, demethoxycurcumin and bisdemethoxycurcumin are potential pancreatic lipase inhibitors in turmeric, which can specifically bind to pancreatic lipase, and the binding strength is bisdemethoxycurcumin < demethoxycurcumin < curcumin.

[0054] (4) Inhibition kinetics of pancreatic lipase by turmeric extract

[0055] The inhibitory effects of curcumin, demethoxycurcumin, and bisdemethoxycurcumin on pancreatic lipase were verified. Figure 2As shown in the figure, the inhibitory effect of curcumin, demethoxycurcumin and bisdemethoxycurcumin on pancreatic lipase increases with the increase of their mass concentration, and the inhibition rate shows a linear relationship with the mass concentration; when the concentration of curcumin, demethoxycurcumin and bisdemethoxycurcumin is higher than , the inhibitory effect tends to be flat. According to the experimental data, the IC values ​​of curcumin, demethoxycurcumin and bisdemethoxycurcumin were calculated by linear fitting within the linear range. 50 The results are 0.24±0.02mg / mL, 1.12±0.05mg / mL and 3.30±0.08mg / mL respectively. This indicates that the inhibitory strength of pancreatic lipase is bisdemethoxycurcumin < demethoxycurcumin < curcumin, which is consistent with the above results.

[0056] In order to further understand the inhibitory mechanism of curcumin, demethoxycurcumin and bisdemethoxycurcumin on PL, the present invention conducted enzyme inhibition kinetic experiments. Figure 3 Specifically, the relationship between the enzymatic reaction rate v and the PL concentration in the presence of different concentrations of curcumin, demethoxycurcumin, and bisdemethoxycurcumin. The results show that all straight lines pass through the origin. In the presence of the same concentration of inhibitor, the concentration of PL is positively correlated with the enzymatic reaction rate v, and the higher the concentration of the inhibitor in the reaction system, the lower the slope of the straight line, which indicates that the inhibition process of curcumin, demethoxycurcumin, and bisdemethoxycurcumin on PL is reversible, and it may be through the form of non-covalent bond binding to the enzyme, thereby causing the reduction or loss of pancreatic lipase activity.

[0057] Further, according to the Lineweaver–Burk double reciprocal method, the relationship between 1 / v and 1 / [p NPB] was evaluated to determine the type of inhibition (competitive, non-competitive, mixed or anti-competitive) of curcumin, demethoxycurcumin and bisdemethoxycurcumin on PL. Figure 4 As shown in (B1), (B2), and (B3), the fitting straight lines of different concentrations of curcumin, demethoxycurcumin, and bisdemethoxycurcumin all intersect on the Y axis, and the slope of the straight line increases with the increase of the concentration of curcumin, demethoxycurcumin, and bisdemethoxycurcumin, while Vmax remains unchanged, indicating that curcumin, demethoxycurcumin, and bisdemethoxycurcumin are typical competitive inhibitors. According to the characteristics of competitive inhibition, it can be inferred that curcumin, demethoxycurcumin, and bisdemethoxycurcumin, as inhibitors, compete with the substrate for the binding site of the active center when binding to pancreatic lipase, thereby achieving an inhibitory effect. The kinetic equation is as follows:

[0058]

[0059] Where I and S represent the concentration of inhibitor and substrate, respectively, ν and Vmax are the enzyme reaction rate and the maximum catalytic reaction rate, Ki and Km represent the inhibitor constant and Michaelis constant, respectively. The slope of each straight line observed has a good linear relationship with the concentration of curcumin, demethoxycurcumin, and bisdemethoxycurcumin (e.g. Figure 4 As shown), it shows that curcumin, demethoxycurcumin, and bisdemethoxycurcumin have one or a class of binding sites in the active center of PL. The inhibition constants Ki values ​​of curcumin, demethoxycurcumin, and bisdemethoxycurcumin calculated according to the equation are (0.24±0.03)ug / mL, (0.28±0.04)ug / mL, and (0.36±0.04)ug / mL. In the competitive inhibition type, the inhibition constant of the enzyme can represent the dissociation constant of the enzyme and inhibitor complex. The size of the Ki value can reflect the degree of dissociation of the enzyme and inhibitor complex, and reflects the inhibitory ability of the inhibitor to the enzyme. Therefore, the order of the catalytic affinity of the three for PL is curcumin>demethoxycurcumin>bisdemethoxycurcumin, which may reduce the catalytic activity of PL by directly competing with the substrate for the active site of PL, thereby exerting its inhibitory effect.

[0060] (5) Fluorescence Spectrum of Pancreatic Lipase Inhibition by Turmeric Extract

[0061] 5.1 Fluorescence quenching analysis

[0062] Fluorescence quenching can be used to study the interaction between protein fluorophores and ligands and their binding affinity and thermodynamic parameters. -6 M) was mixed with different concentrations of curcumin, demethoxycurcumin and bisdemethoxycurcumin at 298K and 310K for 15 min, and the fluorescence emission spectrum of the mixed solution was measured in the range of 300-420nm with an excitation wavelength of 280nm. Both the excitation and emission bandwidths were set to 5nm. Figure 5 Respectively represent the fluorescence quenching of PL by curcumin, demethoxycurcumin, and bisdemethoxycurcumin at room temperature. Obviously, at an excitation wavelength of 280nm, PL shows a maximum fluorescence characteristic peak at 330nm. By increasing the concentrations of curcumin, demethoxycurcumin, and bisdemethoxycurcumin in the reaction system, it can be observed that curcumin, demethoxycurcumin, and bisdemethoxycurcumin can significantly inhibit the fluorescence of PL, and within a certain measurement concentration range, the quenching efficiency of curcumin, demethoxycurcumin, and bisdemethoxycurcumin is positively correlated with PL, indicating that there is an interaction between curcumin, demethoxycurcumin, and bisdemethoxycurcumin and PL.

[0063] According to the Stern–Volmer equation, a graph of the relationship between F0 / F and [Q] is drawn, as follows: Figure 5As shown in the figure, curcumin, demethoxycurcumin and bisdemethoxycurcumin show good linearity at 298, 304 and 310K. In addition, the quenching constants Ksv of curcumin, demethoxycurcumin and bisdemethoxycurcumin are calculated by the above equation. As shown in Table 5, the quenching constants Ksv of curcumin, demethoxycurcumin and bisdemethoxycurcumin decrease with increasing temperature, and the corresponding Kq (Ksv=Kqτ0) values ​​are also much larger than the maximum diffusion collision quenching rate constant of biomolecules (2.0×1010Lmol-1s-1), indicating that the fluorescence quenching type of curcumin, demethoxycurcumin and bisdemethoxycurcumin on PL is single, and the fluorescence quenching of curcumin, demethoxycurcumin and bisdemethoxycurcumin on PL fluorescence belongs to static quenching, which may quench the endogenous fluorescence of PL by forming a stable complex with PL.

[0064] 5.2 Analysis of binding constant, number of binding sites and thermodynamic parameters

[0065] The binding constant (Ka) and the number of binding sites (n) were calculated based on the double logarithmic regression equation. It was found that the binding constant Ka value of curcumin, demethoxycurcumin, and bisdemethoxycurcumin with PL was approximately 10 4 Lmol-1, indicating that curcumin, demethoxycurcumin, and bisdemethoxycurcumin have moderate affinity for PL. In addition, the binding constants Ka of curcumin, demethoxycurcumin, and bisdemethoxycurcumin with PL decrease with increasing temperature, indicating that their binding ability with PL weakens with increasing temperature. At different temperatures, the n values ​​of curcumin, demethoxycurcumin, and bisdemethoxycurcumin are all approximately 1, indicating that curcumin, demethoxycurcumin, and bisdemethoxycurcumin have only one or one type of binding site on PL, which supports the results of Lineweaver–Burk plot analysis.

[0066] By calculating the main thermodynamic parameters, the type of binding force between curcumin, demethoxycurcumin, bisdemethoxycurcumin and PL can be determined. As shown in Table 5, the ΔG of curcumin, demethoxycurcumin and bisdemethoxycurcumin are all <0, indicating that the reactions of curcumin, demethoxycurcumin, bisdemethoxycurcumin and PL are spontaneous. The ΔH<0 and ΔS>0 of curcumin, demethoxycurcumin and bisdemethoxycurcumin indicate that the interaction process between curcumin, demethoxycurcumin and bisdemethoxycurcumin and PL is a dual-driven exothermic process, and hydrophobic forces and hydrogen bonds are the main forces driving the binding of curcumin, demethoxycurcumin and bisdemethoxycurcumin to PL.

[0067] Table 5 Binding constants and thermodynamic constants of the interaction between inhibitors and PL at different temperatures

[0068]

[0069] (6) Molecular docking of pancreatic lipase from turmeric extract

[0070] Molecular docking technology was used to further study the inhibitory mechanism of curcumin, demethoxycurcumin, and bisdemethoxycurcumin on pancreatic lipase, and MOE software was used to study the specific interaction between curcumin, demethoxycurcumin, bisdemethoxycurcumin, and pNPB and PL. The two-dimensional structures of the three small molecules and pNPB were downloaded from PubChem in SDF format, and the structure of pancreatic lipase (PDB ID: 1ETH) was downloaded from Protein Data Bank in PDB format. The water, salt, and ligand of 1ETH were removed, and then all hydrogen atoms and charges were added to minimize the energy of lipase and small molecules. The conformation with the lowest binding conformation score was selected for analysis (Wang et al., 2023). The optimal binding mode was determined based on the binding energy after docking, and the optimal molecular docking simulation result was selected based on the principle that the lower the binding free energy, the tighter the binding of the substance, and the more stable the binding state. Studies have shown that six amino acid residues (Ser (152), Asp (176), His (263), Phe (77), His (151) and Phe (215) are mainly involved in the PL catalytic reaction, among which Ser (152), Asp (176) and His (263) form the acyl enzyme catalytic triad, while Phe (77), His (151) and Phe (215) constitute potential substrate binding or inhibition sites of lipase. The docking results of substrate p-NPB and curcumin, demethoxycurcumin and bisdemethoxycurcumin with pancreatic lipase were studied respectively, and the 3D and 2D images of p-NPB and curcumin, demethoxycurcumin and bisdemethoxycurcumin binding to receptor pancreatic lipase were obtained (such as Figure 6 The results showed that p-NPB ( Figure 6 ) and curcumin, demethoxycurcumin, bisdemethoxycurcumin ( Figure 6) can enter the active site of pancreatic lipase and interact with the amino acid residues in the active center of the enzyme. Specifically, the substrate p-NPB forms a hydrogen bond with the amino acid residue His152 in the active center of the enzyme, forms a hydrophobic force with Gly77, and forms a π bond interaction with Phe215; curcumin forms a π bond interaction with the amino acid residues His264 and Phe215 in the active center of the enzyme, and forms a π-H bond interaction with Ile79; demethoxycurcumin forms a hydrogen bond with the amino acid residue Ser(153) in the active center of the enzyme, and forms a π-H bond interaction with Try115; and bisdemethoxycurcumin forms a hydrogen bond interaction with the amino acid residues Phe(78) and His(152) in the active center of the enzyme. Compared with the substrate p-NPB, it can be seen that the amino acids in the active site of pancreatic lipase bound by the substrate p-NPB of curcumin, demethoxycurcumin, and bisdemethoxycurcumin are similar, indicating that curcumin, demethoxycurcumin, and bisdemethoxycurcumin can compete with p-NPB for the active center of the enzyme. By occupying the active center of the enzyme, the substrate p-NPB cannot enter the active pocket, thereby causing the enzyme activity to decrease, which is a competitive inhibition. This molecular docking result is consistent with the inhibition kinetics result. In addition, the binding affinity of curcumin, demethoxycurcumin, and bisdemethoxycurcumin to lipase is -7.05kcal / mol, -6.68kcal / mol, and -6.44kcal / mol, respectively, indicating that the affinity of the three to pancreatic lipase is curcumin>demethoxycurcumin>bisdemethoxycurcumin, which is also consistent with the enzyme inhibition kinetics result.

[0071] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. Application of a curcuminoid compound in the preparation of a pancreatic lipase inhibitor, wherein the curcuminoid compound comprises one or more of curcumin, bisdemethoxycurcumin and demethoxycurcumin.

2. The use according to claim 1, characterized in that: The curcuminoids inhibit pancreatic lipase.

3. A method for extracting curcuminoids, characterized in that: The following steps are involved: 1) mixing turmeric with a deep eutectic solvent, and extracting by microwave-assisted method to obtain an extract; 2) Centrifuging the extract obtained in step 1) to obtain a supernatant, and quantifying the supernatant by high performance liquid chromatography to obtain curcuminoids.

4. The extraction method according to claim 3, characterized in that In the step 1), the solid-liquid ratio of turmeric to the deep eutectic solvent is 1:10-1:

20.

5. The extraction method according to claim 3 or 4, characterized in that The low eutectic solvent in step 1) is choline chloride and lactic acid, and the molar ratio of choline chloride to lactic acid is 2:1-1:

2.

6. The extraction method according to claim 3, characterized in that The extraction temperature in step 1) is 50-70° C. and the extraction time is 10-30 min.

7. The extraction method according to claim 3, characterized in that The centrifugal conditions in step 2) include: a rotation speed of 4000 rpm and a time of 5-15 min.

Citation Information

Patent Citations

  • Preparation method of high-purity natural curcumin product

    CN106046850A

  • Seaweed fruit and vegetable formula assisting in reducing fat and losing weight

    CN111449243A